Enhertu
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu in HER2-Ultralow Breast Cancer
The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.
HER2 Biomarker Evolving as Enhertu Shows Activity in Breast Cancers With Ultralow Expression
Premium
The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists revisiting patients' old test results.
NICE Not Backing AstraZeneca, Daiichi Sankyo's Enhertu in HER2-Low Breast Cancer
Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.
AstraZeneca, Daiichi Sankyo Hoping to Sway FDA of Dato-DXd Benefit Despite Overall Survival Miss
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
At ESMO, Multiple Enhertu Studies Highlight Challenges of Selecting, Managing Breast Cancer Patients
Premium
Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.